Q3 EPS Forecast for 4D Molecular Therapeutics Cut by Analyst

Key Points

• 4D Molecular Therapeutics has seen its Q3 EPS forecast cut from ($0.88) to ($0.98) by the analyst firm Leerink Partners.
• The company reported a significant loss of ($0.98) EPS for the recent quarter, missing consensus estimates by ($0.10).
• Institutional investors have increased their stakes in 4D Molecular Therapeutics, with 99.27% of the stock owned by hedge funds and other institutional investors.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at Leerink Partnrs cut their Q3 2025 earnings estimates for shares of 4D Molecular Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.98) per share for the quarter, down from their prior forecast of ($0.88). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics' Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.82) EPS and FY2026 earnings at ($3.79) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million.

Other equities analysts have also issued research reports about the stock. Roth Capital reduced their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, July 29th. Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday. The Goldman Sachs Group dropped their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Barclays dropped their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.40.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $6.67 on Thursday. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $17.41. The firm's fifty day moving average is $4.56 and its 200 day moving average is $4.11. The firm has a market cap of $308.99 million, a P/E ratio of -1.89 and a beta of 2.83.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Federated Hermes Inc. increased its stake in shares of 4D Molecular Therapeutics by 33.4% in the 2nd quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company's stock worth $6,186,000 after acquiring an additional 417,157 shares in the last quarter. Marshall Wace LLP increased its stake in shares of 4D Molecular Therapeutics by 62.8% in the 2nd quarter. Marshall Wace LLP now owns 257,620 shares of the company's stock worth $956,000 after acquiring an additional 99,332 shares in the last quarter. Invesco Ltd. increased its stake in shares of 4D Molecular Therapeutics by 19.2% in the 2nd quarter. Invesco Ltd. now owns 140,325 shares of the company's stock worth $521,000 after acquiring an additional 22,557 shares in the last quarter. Norges Bank bought a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth about $201,000. Finally, Quadrature Capital Ltd bought a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth about $42,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.